Cyclooxygenase-2 inhibitors dilemma in cardiovascular medicine: are all family members bad players?
Cyclooxygenase-2 (COX-2) inhibitors dilemma in cardiovascular medicine has not been resolved yet. The cardiovascular safety of selective COX-2 inhibitors other than rofecoxib is uncertain. Given the ongoing controversy surrounding the use of COX-2 inhibitors, further clinical studies with different types of drugs are required to establish safety and therapeutic benefit in patients with coronary artery disease.
Celik
Turgay
T
Iyisoy
Atila
A
Kursaklioglu
Hurkan
H
Yuksel
U Cagdas
UC
D002319:Cardiovascular System / Q000187:drug effects*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans
D052246:Cyclooxygenase 2 Inhibitors